Novaremed, a privately held clinical-stage biopharmaceutical company, expands its pipeline of non-opioid treatment candidates for chronic pain indications through the acquisition of Metys Pharmaceuticals. The acquisition broadens Novaremed’s existing pipeline by adding both
Tags :Matthias Staehelin
EnBiotix, a Boston-based biotech company focused on rare diseases, is merging with Swiss oncology and antimicrobial resistance-focused company Polyphor. A merger agreement under which Polyphor will use all of EnBiotix’s outstanding share capital in
Kuros Biosciences, a bone graft technologies company, has entered into a royalty purchase agreement with Xoma Corporation, under which Xoma has purchased a proportion of the potential future pre-commercial milestone payments and all the potential
Vischer has acted as legal counsel to TargImmune Therapeutics, a private Swiss-based biotechnology firm, on the closing of its 2021 financing round, raising CHF 17.7 million. The Vischer legal team was led by Matthias Staehelin (pictured) with
Novartis has signed a collaboration agreement and option to acquire Cellerys, a Zurich-based start-up that is researching a therapy to combat multiple sclerosis (MS). This therapy has the potential to delay the progression of the
Swiss Nuclides, a developer of novel radionuclide Pet tracers for the precision diagnostics, has closed the first tranche of its series A financing round, raising CHF 2.6 million from private investors. Vischer has been acting as
Oculis has closed an oversubscribed USD 57m Series C financing round. It was co-led by new investors BVCF Management and Hyfinity Investments, with VI Partners and Wille AG joining the company’s existing investors, Bay
Drägerwerk AG & Co. KGaA, an international operator in the fields of medical and safety technology, has acquired a majority stake in the Swiss-based start-up medical technology company STIMIT. VISCHER advised Stimit and the
VISCHER has been advising credentis since 2010 in all financing rounds and strategic partnerships and assisted credentis and its shareholders also in this sale concluding a decade long collaboration. The team was led by Matthias Staehelin (
The team was led by Matthias Staehelin (pictured) and Moritz Jäggy with Sebastian Flückiger and Pauline Pfirter (all Corporate). Partners David Rosenthal (Data Privacy) and Nadia Tarolli (Tax) assisted as well.
